Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Operating Margin (2021 - 2025)

Tarsus Pharmaceuticals has reported Operating Margin over the past 5 years, most recently at 5.26% for Q4 2025.

  • Quarterly results put Operating Margin at 5.26% for Q4 2025, up 3152.0% from a year ago — trailing twelve months through Dec 2025 was 15.72% (up 5018.0% YoY), and the annual figure for FY2025 was 15.72%, up 5018.0%.
  • Operating Margin for Q4 2025 was 5.26% at Tarsus Pharmaceuticals, up from 12.24% in the prior quarter.
  • Over the last five years, Operating Margin for TARS hit a ceiling of 33.07% in Q2 2021 and a floor of 4274.56% in Q4 2021.
  • Median Operating Margin over the past 5 years was 66.94% (2024), compared with a mean of 732.67%.
  • Peak annual rise in Operating Margin hit 412395bps in 2022, while the deepest fall reached -365375bps in 2022.
  • Tarsus Pharmaceuticals' Operating Margin stood at 4274.56% in 2021, then surged by 96bps to 150.61% in 2022, then crashed by -126bps to 339.94% in 2023, then soared by 89bps to 36.77% in 2024, then surged by 86bps to 5.26% in 2025.
  • The last three reported values for Operating Margin were 5.26% (Q4 2025), 12.24% (Q3 2025), and 21.61% (Q2 2025) per Business Quant data.